Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 899 KB
Released: March 5, 2021

Acknowledgements

Produced in collaboration with
Supported by an educational grant from
Lilly

Related Content

MONALEESA-3 updated survival analysis with ribociclib + fulvestrant in advanced breast cancer, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

GeparNUEVO survival outcomes with durvalumab + neoadjuvant chemo in early triple-negative breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

OlympiA interim analysis of adjuvant olaparib in BRCA-mutated, HER2-negative early breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 9, 2021

ASCENT patient subgroup analyses for sacituzumab govitecan vs chemotherapy in metastatic triple-negative breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue